DRIVING VACCINE DEVELOPMENT
Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with vaccines-related conditions. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.
On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.
Vaccines Pipeline & Trials
Vaccines as of April 28, 2020
- Discovery Projects
- 1Phase 1
- 4Phase 2
- 2Phase 3
- 0Registration
- Total7
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
PF-06425090 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: Biopharma Mechanism of Action: Prophylactic Vaccine | Primary clostridioides difficile infection (FAST TRACK) | Phase 3 | New Molecular Entity | Vaccine |
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: Biopharma Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (Adult) (BREAKTHROUGH) | Phase 3 | New Molecular Entity | Vaccine |
PF-06760805 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive Group B Streptococcus Infection (maternal) | Phase 2 | New Molecular Entity | Vaccine |
PF-06842433 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (infants and children) | Phase 2 | New Molecular Entity | Vaccine |
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Serogroups ABCWY Meningococcal Infections (adolescent and young adults) | Phase 2 | New Molecular Entity | Vaccine |
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Respiratory Syncytial Virus Infection (maternal) | Phase 2 | New Molecular Entity | Vaccine |
PF-07302048 (BNT162) Therapeutic Area: Vaccines Phase:Phase 1 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in partnership with BioNTech)
Project advanced | Phase 1 | New Molecular Entity | Vaccine |
